For how we live.
A meta-analysis of 90,000 people found these diabetes-origin drugs reduced kidney disease progression by 37% and cardiovascular events by 23%, and the benefit was similar in people who did not have diabetes.
The prices apply only to 10 drugs, only in Medicare, and only from January 2026. Here is exactly which drugs, by how much, and who actually sees the difference.
A first consolidated audit of PBS and PHARMAC cardiovascular listings from 2023 to 2025 finds a widening access gap between two neighbouring countries with similar disease burdens.
Pooling individual data from 23,340 people in four trials, empagliflozin cut kidney failure by 34% and slowed eGFR decline by 64% — regardless of how big an initial creatinine rise was expected.